These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 8174119)

  • 1. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma.
    Miyake Y; Kodama T; Yamaguchi K
    Cancer Res; 1994 Apr; 54(8):2136-40. PubMed ID: 8174119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pro-gastrin-releasing peptide (Pro-GRP), a tumor marker for small cell lung cancer.
    Oremek GM; Sapoutzis N
    Anticancer Res; 2003; 23(2A):895-8. PubMed ID: 12820319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma.
    Maruno K; Yamaguchi K; Abe K; Suzuki M; Saijo N; Mishima Y; Yanaihara N; Shimosato Y
    Cancer Res; 1989 Feb; 49(3):629-32. PubMed ID: 2535962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
    Schneider J; Philipp M; Salewski L; Velcovsky HG
    Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer.
    Uchida K; Kojima A; Morokawa N; Tanabe O; Anzai C; Kawakami M; Eto Y; Yoshimura K
    J Cancer Res Clin Oncol; 2002 Dec; 128(12):633-40. PubMed ID: 12474049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ProGRP: a new biomarker for small cell lung cancer.
    Molina R; Filella X; Augé JM
    Clin Biochem; 2004 Jul; 37(7):505-11. PubMed ID: 15234231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical significance of ProGRP31-98 in patients with small-cell lung cancer].
    Yang J; Li R; Li A
    Zhonghua Zhong Liu Za Zhi; 2000 May; 22(3):216-8. PubMed ID: 11778234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
    Bubanović G; Pavićević R; Franjević A
    Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
    Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
    Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction.
    Kamata K; Uchida M; Takeuchi Y; Takahashi E; Sato N; Miyake Y; Okubo M; Kodama T; Yamaguchi K
    Nephrol Dial Transplant; 1996 Jul; 11(7):1267-70. PubMed ID: 8672021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of osteoprotegerin (OPG) and pro gastrin releasing peptide (ProGRP) during chemotherapy of lung cancer.
    Naumnik W; Chyczewska E; Izycki T; Ossolinska M
    Rocz Akad Med Bialymst; 2004; 49 Suppl 1():88-90. PubMed ID: 15638385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
    Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
    Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer.
    Okusaka T; Eguchi K; Kasai T; Kurata T; Yamamoto N; Ohe Y; Tamura T; Shinkai T; Saijo N
    Clin Cancer Res; 1997 Jan; 3(1):123-7. PubMed ID: 9815547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
    Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma, compared with neuron-specific enolase].
    Maruno K
    Nihon Geka Gakkai Zasshi; 1990 Jun; 91(6):760-5. PubMed ID: 2169019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
    Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
    Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pro gastrin-releasing peptide (ProGRP)].
    Ishikawa H; Saito T
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():759-61. PubMed ID: 16149633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.